Matthew Sykes
Stock Analyst at Goldman Sachs
(4.02)
# 585
Out of 5,042 analysts
210
Total ratings
55.48%
Success rate
10.14%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $11.30 | -55.75% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $4.26 | -29.58% | 14 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $13.77 | -52.80% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $39.00 | +15.38% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $8.15 | -1.84% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $34.11 | +40.72% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $16.86 | +0.83% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $178.11 | -10.17% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $10.67 | -6.28% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $98.89 | +26.40% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $15.40 | -9.09% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $223.01 | +7.62% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $14.97 | +73.68% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $197.04 | -13.72% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $72.15 | -22.38% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $128.87 | -37.92% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $2.02 | -25.74% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $192.51 | -1.30% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $1.22 | +43.44% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $3.41 | +24.63% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $36.73 | +0.74% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $75 → $65 | $64.64 | +0.56% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $220.52 | +13.37% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $5.72 | +319.58% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,434.32 | -9.36% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $13.57 | -11.57% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $572.50 | +11.79% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $148.03 | -2.05% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $49.32 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $11.30
Upside: -55.75%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $4.26
Upside: -29.58%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $13.77
Upside: -52.80%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $39.00
Upside: +15.38%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $8.15
Upside: -1.84%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $34.11
Upside: +40.72%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $16.86
Upside: +0.83%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $178.11
Upside: -10.17%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $10.67
Upside: -6.28%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $98.89
Upside: +26.40%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $15.40
Upside: -9.09%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $223.01
Upside: +7.62%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $14.97
Upside: +73.68%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $197.04
Upside: -13.72%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $72.15
Upside: -22.38%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $128.87
Upside: -37.92%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $2.02
Upside: -25.74%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $192.51
Upside: -1.30%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $1.22
Upside: +43.44%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $3.41
Upside: +24.63%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $36.73
Upside: +0.74%
Nov 6, 2024
Maintains: Buy
Price Target: $75 → $65
Current: $64.64
Upside: +0.56%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $220.52
Upside: +13.37%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $5.72
Upside: +319.58%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,434.32
Upside: -9.36%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $13.57
Upside: -11.57%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $572.50
Upside: +11.79%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $148.03
Upside: -2.05%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $49.32
Upside: -